Fig. 5: Therapeutic approaches in metastatic TNBC (red: current approaches, Blue: future directions).

ADC antibody drug conjugate; PARPi: poly-ADP ribose polymerase inhibitors; HRD homologous recombination deficiency; AR androgen receptors. Figure includes modified templates from Servier Medical Art (smart.servier.com).